通心络胶囊联合西药治疗对冠心病患者血管内皮功能及炎症因子水平的影响
|
摘要
目的:探讨通心络胶囊联合西药治疗对冠心病患者血管内皮功能及炎症因子水平的影响。方法:选取本院收治的冠心病患者86例,按照随机数字表法将其分为观察组和对照组,各43例。对照组予以常规西药治疗,观察组在对照组基础上联合通心络胶囊治疗,比较两组治疗前后心功能、血管内皮功能、炎症因子水平以及两组的治疗效果。结果:观察组总有效率为90.70%,高于对照组的72.09%(P<0.05);治疗后,观察组LVEF、CO、E/A水平均高于治疗前及对照组(P<0.05);治疗后,观察组ET-1、TXB2水平均低于治疗前及对照组,NO水平高于治疗前及对照组,差异均有统计学意义(P<0.05);治疗后,观察组CRP、IL-6、TNF-α水平均低于治疗前及对照组(P<0.05)。结论:通心络胶囊联合西药治疗冠心病效果确切,可有效改善患者心功能,减轻血管内皮细胞损伤程度,降低炎性反应。
Objective:To investigate the effects of Tongxinluo Capsule combined with western medicine on vascular endothelial function and inflammatory factors in patients with coronary heart disease.Method:A total of86 patients with coronary heart disease admitted to our hospital were selected.According to the random number table method,they were divided into observation group and control group,43 cases in each group.The control group was treated with conventional western medicine,while observation group was treated with Tongxinluo Capsule on the basis of control group.The cardiac function,vascular endothelial function,levels of inflammatory factors before and after treatment,and curative effect between two groups were compared.Result:The total effective rate was 90.70%in observation group,which was higher than 72.09% in control group(P<0.05).After treatment,the levels of LVEF,CO and E/A in observation group were higher than those of before treatment and control group(P<0.05).After treatment,the levels of ET-1 and TXB2 in observation group were lower than those of before treatment and control group,the level of NO in observation group was higher than those of before treatment and control group,the differences were statistically significant(P<0.05).After treatment,the levels of CRP,IL-6 and TNF-α in observation group were lower than those of before treatment and control group(P<0.05).Conclusion:Tongxinluo Capsule combined with western medicine is effective in treatment of coronary heart disease,which can effectively improve the heart function,reduce the degree of vascular endothelial cell damage and reduce the inflammatory response.
Objective:To investigate the effects of Tongxinluo Capsule combined with western medicine on vascular endothelial function and inflammatory factors in patients with coronary heart disease.Method:A total of86 patients with coronary heart disease admitted to our hospital were selected.According to the random number table method,they were divided into observation group and control group,43 cases in each group.The control group was treated with conventional western medicine,while observation group was treated with Tongxinluo Capsule on the basis of control group.The cardiac function,vascular endothelial function,levels of inflammatory factors before and after treatment,and curative effect between two groups were compared.Result:The total effective rate was 90.70%in observation group,which was higher than 72.09% in control group(P<0.05).After treatment,the levels of LVEF,CO and E/A in observation group were higher than those of before treatment and control group(P<0.05).After treatment,the levels of ET-1 and TXB2 in observation group were lower than those of before treatment and control group,the level of NO in observation group was higher than those of before treatment and control group,the differences were statistically significant(P<0.05).After treatment,the levels of CRP,IL-6 and TNF-α in observation group were lower than those of before treatment and control group(P<0.05).Conclusion:Tongxinluo Capsule combined with western medicine is effective in treatment of coronary heart disease,which can effectively improve the heart function,reduce the degree of vascular endothelial cell damage and reduce the inflammatory response.
引文
[1]梁鹍,董守仁,彭欢,等.复方丹参滴丸联合阿司匹林治疗冠心病的临床观察[J].中国药房,2016,27(32):4555-4558.
[2]李丽,曹学彬,王晶璞,等.通心络胶囊联合艾司洛尔治疗冠心病心肌缺血的疗效观察[J].现代药物与临床,2016,31(7):1012-1015.
[3]K?hk?nen O,Saaranen T,Kankkunen P,et al.Predictors of adherence to treatment by patients with coronary heart disease after percutaneous coronary intervention[J].J Clin Nurs,2018,27(5-6):989-1003.
[4]李玉敏.血脂康胶囊联合氨氯地平阿托伐他汀钙片治疗高血压并冠心病的临床疗效及其对血脂、血管内皮功能及炎症的影响[J].实用心脑肺血管病杂志,2016,24(7):90-93.
[5]第一届全国内科学术会议心血管病组.关于冠状动脉性心脏病命名及诊断标准的建议[J].中华心血管病杂志,1981,16(9):75-76.
[6]中华人民共和国卫生部.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:68-73.
[7]茶永芳.稳心颗粒结合美托洛尔治疗冠心病合并心律失常的效果观察[J].中国急救医学,2017,37(Z2):13-14.
[8]袁玉亮,王娜.丹参多酚酸盐治疗冠心病的效果及对患者免疫炎症反应的影响[J].国际免疫学杂志,2018,41(2):238-242.
[9]Farquhar J M,Stonerock G L,Blumenthal J A.Treatment of Anxiety in Patients With Coronary Heart Disease:A Systematic Review[J].Psychosomatics,2018,59(4):318-332.
[10]王国菊,陈运海,毛丽娟.稳心颗粒联合美托洛尔治疗老年人冠心病心律失常的疗效及其安全性分析[J].中国生化药物杂志,2017,37(6):325-327.
[11]吕冬,曾维富.通心络胶囊联合美托洛尔治疗冠心病室性心律失常的临床疗效观察[J].实用心脑肺血管病杂志,2016,24(11):79-82.
[12]汪莲开.通心络胶囊治疗老年冠心病的疗效及机制[J].中国老年学杂志,2016,36(6):1321-1322.
[13]严建军,刘倩,张贞胜,等.血清内脏脂肪素水平与冠心病患者氧化应激、颈动脉粥样硬化的相关性及通心络胶囊的干预作用[J].实用心脑肺血管病杂志,2018,26(4):54-57,62.
[14]常国栋,陈英伟,许学升,等.通心络胶囊治疗冠心病的疗效及机制研究[J].中国循证心血管医学杂志,2018,10(6):729-732.
[15]付强,齐霁.谷红注射液辅助治疗冠心病患者PCI术后再发心绞痛的临床疗效及其对炎性因子和血管内皮功能的影响[J].医学临床研究,2018,35(1):79-82.
[16]陶智军.曲美他嗪联合美托洛尔治疗冠心病心力衰竭对血管内皮功能及氧化应激指标的影响[J].中国临床医生杂志,2018,46(6):667-670.
[17]袁斐,罗心平.通心络胶囊联合美托洛尔缓释片对冠心病血管内皮功能和心功能指标的影响[J].中国慢性病预防与控制,2016,24(4):300-302.
[18]李光智,王建军.复方丹参滴丸在治疗冠心病及改善血清炎症因子水平中的应用价值[J].中国老年学杂志,2017,37(11):2663-2664.
[19]王永智,浦奎.自拟益气祛瘀方辅助西药治疗冠心病心衰疗效及对心功能、炎症相关细胞因子水平的影响[J].中国中医急症,2018,27(6):1053-1056.
[20]李泉,陈国宁,高伟铿,等.通心络胶囊联合阿托伐他汀对老年冠心病不稳定型心绞痛患者血脂和炎性因子的影响[J].中国药业,2018,27(14):32-34.
[2]李丽,曹学彬,王晶璞,等.通心络胶囊联合艾司洛尔治疗冠心病心肌缺血的疗效观察[J].现代药物与临床,2016,31(7):1012-1015.
[3]K?hk?nen O,Saaranen T,Kankkunen P,et al.Predictors of adherence to treatment by patients with coronary heart disease after percutaneous coronary intervention[J].J Clin Nurs,2018,27(5-6):989-1003.
[4]李玉敏.血脂康胶囊联合氨氯地平阿托伐他汀钙片治疗高血压并冠心病的临床疗效及其对血脂、血管内皮功能及炎症的影响[J].实用心脑肺血管病杂志,2016,24(7):90-93.
[5]第一届全国内科学术会议心血管病组.关于冠状动脉性心脏病命名及诊断标准的建议[J].中华心血管病杂志,1981,16(9):75-76.
[6]中华人民共和国卫生部.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:68-73.
[7]茶永芳.稳心颗粒结合美托洛尔治疗冠心病合并心律失常的效果观察[J].中国急救医学,2017,37(Z2):13-14.
[8]袁玉亮,王娜.丹参多酚酸盐治疗冠心病的效果及对患者免疫炎症反应的影响[J].国际免疫学杂志,2018,41(2):238-242.
[9]Farquhar J M,Stonerock G L,Blumenthal J A.Treatment of Anxiety in Patients With Coronary Heart Disease:A Systematic Review[J].Psychosomatics,2018,59(4):318-332.
[10]王国菊,陈运海,毛丽娟.稳心颗粒联合美托洛尔治疗老年人冠心病心律失常的疗效及其安全性分析[J].中国生化药物杂志,2017,37(6):325-327.
[11]吕冬,曾维富.通心络胶囊联合美托洛尔治疗冠心病室性心律失常的临床疗效观察[J].实用心脑肺血管病杂志,2016,24(11):79-82.
[12]汪莲开.通心络胶囊治疗老年冠心病的疗效及机制[J].中国老年学杂志,2016,36(6):1321-1322.
[13]严建军,刘倩,张贞胜,等.血清内脏脂肪素水平与冠心病患者氧化应激、颈动脉粥样硬化的相关性及通心络胶囊的干预作用[J].实用心脑肺血管病杂志,2018,26(4):54-57,62.
[14]常国栋,陈英伟,许学升,等.通心络胶囊治疗冠心病的疗效及机制研究[J].中国循证心血管医学杂志,2018,10(6):729-732.
[15]付强,齐霁.谷红注射液辅助治疗冠心病患者PCI术后再发心绞痛的临床疗效及其对炎性因子和血管内皮功能的影响[J].医学临床研究,2018,35(1):79-82.
[16]陶智军.曲美他嗪联合美托洛尔治疗冠心病心力衰竭对血管内皮功能及氧化应激指标的影响[J].中国临床医生杂志,2018,46(6):667-670.
[17]袁斐,罗心平.通心络胶囊联合美托洛尔缓释片对冠心病血管内皮功能和心功能指标的影响[J].中国慢性病预防与控制,2016,24(4):300-302.
[18]李光智,王建军.复方丹参滴丸在治疗冠心病及改善血清炎症因子水平中的应用价值[J].中国老年学杂志,2017,37(11):2663-2664.
[19]王永智,浦奎.自拟益气祛瘀方辅助西药治疗冠心病心衰疗效及对心功能、炎症相关细胞因子水平的影响[J].中国中医急症,2018,27(6):1053-1056.
[20]李泉,陈国宁,高伟铿,等.通心络胶囊联合阿托伐他汀对老年冠心病不稳定型心绞痛患者血脂和炎性因子的影响[J].中国药业,2018,27(14):32-34.